FDA approves Merck's Lipfendra, a once-daily oral PCSK9 inhibitor for lowering LDL cholesterol
Enlicitide cut LDL-C by 56% against placebo in a 2,904-patient trial, putting PCSK9 inhibition into a once-daily tablet.
FDA approves Merck's Idvynso, a doravirine and islatravir tablet, four years after a clinical hold on islatravir
Doravirine and islatravir matched Biktarvy in a switch trial, with the islatravir dose cut to 0.25 mg after a 2021 clinical hold.